Assessing the Immunomodulatory Effect of Size on the Uptake and Immunogenicity of Influenza- and Hepatitis B Subunit Vaccines In Vitro.

dendritic cells drug delivery systems flow cytometry hepatitis B virus human peripheral blood mononuclear cells in vitro influenza virus microparticles nanoparticles subunit vaccines

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
18 Jul 2022
Historique:
received: 08 06 2022
revised: 14 07 2022
accepted: 14 07 2022
entrez: 27 7 2022
pubmed: 28 7 2022
medline: 28 7 2022
Statut: epublish

Résumé

Viral subunit vaccines are a safer and more tolerable alternative to whole inactivated virus vaccines. However, they often come with limited efficacy, necessitating the use of adjuvants. Using free and particle-bound viral antigens, we assessed whether size affects the uptake of those antigens by human monocyte-derived dendritic cells (Mo-DCs) and whether differences in uptake affect their capacity to stimulate cytokine production by T cells. To this end, influenza antigens and hepatitis B surface antigen (HBsAg) were covalently conjugated to polystyrene particles of 500 nm and 3 μm. Cellular uptake of the antigens, either unconjugated or conjugated, and their capacity to stimulate T cells within a population of human peripheral blood mononuclear cells (PBMCs) were measured by flow cytometry. Conjugation of both antigens to particles significantly increased their uptake by Mo-DCs. Moreover, both the 500 nm and 3 μm influenza conjugates induced significantly higher numbers of cytokine-producing CD4

Identifiants

pubmed: 35890185
pii: ph15070887
doi: 10.3390/ph15070887
pmc: PMC9321264
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : European Union Seventh Framework Program 19 (FP7/2007-2013) Universal Influenza Vaccines Secured (UNISEC) consortium
ID : 602012
Organisme : Swiss National Science Foundation
ID : CRSII5_180323
Pays : Switzerland

Références

Pharm Res. 2003 Feb;20(2):221-8
pubmed: 12636160
Anal Biochem. 2005 Jan 1;336(1):132-4
pubmed: 15582568
Anal Biochem. 1977 Dec;83(2):346-56
pubmed: 603028
Vaccine. 2014 Jan 9;32(3):327-37
pubmed: 24295808
Int J Pharm. 2021 Apr 15;599:120422
pubmed: 33647407
J Control Release. 2001 Sep 11;76(1-2):59-71
pubmed: 11532313
J Control Release. 2015 Dec 28;220(Pt A):141-148
pubmed: 26437263
Pharm Res. 2008 Aug;25(8):1815-21
pubmed: 18373181
Biomaterials. 2007 Dec;28(35):5344-57
pubmed: 17825905
Expert Opin Drug Deliv. 2016;13(2):167-70
pubmed: 26578092
Int J Pharm. 2005 Sep 14;301(1-2):149-60
pubmed: 16023313
Drug Discov Today. 2011 Jul;16(13-14):569-82
pubmed: 21570475
J Control Release. 2010 Jun 1;144(2):118-26
pubmed: 20156497
Int J Pharm. 2005 Jul 25;298(2):315-22
pubmed: 15961266
Vaccines (Basel). 2017 Aug 09;5(3):
pubmed: 28792466
J Immunol. 1998 Dec 1;161(11):5855-61
pubmed: 9834064
PLoS Pathog. 2008 Aug 29;4(8):e1000138
pubmed: 18769719
Vaccine. 2011 Aug 11;29(35):5824-36
pubmed: 21718746
Pharm Dev Technol. 2011 Feb;16(1):65-74
pubmed: 20088679
Pharm Res. 2001 Mar;18(3):352-60
pubmed: 11442276
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Biotechniques. 2014 Jul 01;57(1):39-44
pubmed: 25005692
Future Sci OA. 2015 Nov 01;1(4):FSO63
pubmed: 28031915
Annu Rev Immunol. 2021 Apr 26;39:759-790
pubmed: 33710920
J Cell Mol Med. 2017 Sep;21(9):1668-1686
pubmed: 28244656
Hum Vaccin. 2008 Jan-Feb;4(1):44-9
pubmed: 18438105
J Control Release. 2016 Jul 28;234:124-34
pubmed: 27221070
Vaccines (Basel). 2016 Apr 19;4(2):
pubmed: 27104575
Int J Nanomedicine. 2014 Aug 13;9:3885-902
pubmed: 25152619
Vaccines (Basel). 2019 Nov 13;7(4):
pubmed: 31766202
PLoS Med. 2010 Mar 30;7(3):e1000245
pubmed: 20361020
Vaccine. 2002 Nov 22;21(1-2):67-77
pubmed: 12443664
Am J Respir Cell Mol Biol. 2013 Jul;49(1):67-77
pubmed: 23492193
J Immunol. 2004 Sep 1;173(5):3148-54
pubmed: 15322175
Nat Rev Immunol. 2010 Nov;10(11):787-96
pubmed: 20948547

Auteurs

Rick Heida (R)

Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, 9713 AV Groningen, The Netherlands.

Philip A Born (PA)

Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, 9713 AV Groningen, The Netherlands.

Gabriela Tapia-Calle (G)

Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, 9713 AV Groningen, The Netherlands.

Henderik W Frijlink (HW)

Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, 9713 AV Groningen, The Netherlands.

Anna Salvati (A)

Department of Nanomedicine and Drug Targeting, University of Groningen, 9713 AV Groningen, The Netherlands.

Anke L W Huckriede (ALW)

Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, 9713 AV Groningen, The Netherlands.

Wouter L J Hinrichs (WLJ)

Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, 9713 AV Groningen, The Netherlands.

Classifications MeSH